Secondary prevention of atherothrombotic events after ischemic stroke

Mayo Clinic Proceedings

Volumn 84, Issue 1, 2009, Pages 43-51

  Adams Jr , Harold P ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; EZETIMIBE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MEGLITINIDE; NICOTINIC ACID; PLACEBO; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; TICLOPIDINE;

ABDOMINAL DISCOMFORT; ANGIOPLASTY; BLEEDING; BRAIN HEMORRHAGE; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CEREBROVASCULAR ACCIDENT; CIGARETTE SMOKING; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY THROMBOSIS; DIABETES MELLITUS; DIARRHEA; DIET THERAPY; DRUG WITHDRAWAL; ENDOVASCULAR SURGERY; EXERCISE; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIGH POTASSIUM INTAKE; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; MONOTHERAPY; NEUTROPENIA; PATIENT CARE; RASH; RECURRENT DISEASE; REVIEW; SMOKING CESSATION; SODIUM RESTRICTION; STENT; STROKE; THROMBOSIS PREVENTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK; WEIGHT REDUCTION; ATHEROSCLEROSIS; BRAIN ISCHEMIA; METHODOLOGY; RISK FACTOR; SECONDARY PREVENTION; THROMBOSIS;

ATHEROSCLEROSIS; BRAIN ISCHEMIA; HUMANS; RISK FACTORS; SECONDARY PREVENTION; THROMBOSIS;

EID: 58749090030     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/84.1.43     Document Type: Review

References (88)

1. Rosamond W, Flegal K, Furie K, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008 Jan 29;117(4):e25-e146. Epub 2007 Dec 17.
2. Albers GW, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest. 1998;114(5)(suppl):683S-698S.
3. Steg PG, Bhatt DL, Wilson PWF et al; REACH Registry Investigators. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297(11):1197-1206.
4. Bravata DM, Ho SY, Meehan TP, Brass LM, Concato J. Readmission and death after hospitalization for acute ischemic stroke: 5-year follow-up in the Medicare population. Stroke. 2007 Jun;38(6):1899-1904. Epub 2007 May 17.
5. Rothwell PM. The interrelation between carotid, femoral and coronary artery disease [editorial]. Eur Heart J. 2001;22(1):11-14.
6. Adams RJ, Chimowitz MI, Alpert JS, et al. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Circulation. 2003;108(10):1278-1290.
7. Fayad P. Secondary prevention measures after a stroke - should they target stroke or heart disease? Nat Clin Pract Neurol. 2006;2(12):646-647.
8. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2006;47(10):2130-2139.
9. Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2008 May;39(5):1647-1652. Epub 2008 Mar 5.
10. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention. Stroke. 2006;37(2):577-617.
11. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thombolytic Therapy. Chest. 2004;126(3)(suppl):483S- 512S.
12. Bornstein N, Silvestrelli G, Caso V, Parnetti L. Arterial hypertension and stroke prevention: an update. Clin Exp Hypertens. 2006;28(3-4):317-326.
13. MacMahon S, Rodgers A. Blood pressure, antihypertensive treatment and stroke risk. J Hypertens Suppl. 1994;12(10):S5-S14.
14. Alexander RW. Hypertension and the pathogenesis of atherosclerosis: oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension. 1995;25(2):155-161.
15. Castillo J, Leira R, García MM, Serena J, Blanco M, Dávalos A. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke. 2004 Feb;35(2):520-526. Epub 2004 Jan 15.
16. Chalmers J. The management of blood pressure in acute stroke. Lancet Neurol. 2003;2(10):593.
17. Goldstein LB. Blood pressure management in patients with acute ischemic stroke [published correction appears in Hypertension. 2004;43(5):e35]. Hypertension. 2004 Feb;43(2):137-141. Epub 2004 Jan 12.
18. CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post-Stroke) pilot trial: rationale and design. J Hypertens. 2005;23(3):649-655.
19. Schrader J, Lüders S, Kulschewski A, et al; ACCESS Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke. 2003 Jul;34(7):1699-1703. Epub 2003 Jun 19.
20. Adams HP Jr, Adams RJ, Brott T, et al. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke. 2003;34(4):1056-1083.
21. Lawes CM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: an overview of published reviews [published correction appears in Stroke. 2004;35(3):776-785]. Stroke. 2004;35(4):1024.
22. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke. 2003 Nov;34(11):2741-2748. Epub 2003 Oct 23.
23. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure lowering regiments on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527-1535.
24. Chobanian AV, Bakris GL, Black HR, et al; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 Dec;42(6):1206-1252. Epub 2003 Dec 1.
25. Enseleit F, Hürlimann D, Lüscher TF. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events. J Cardiovasc Pharmacol. 2001;37(suppl 1):S21-S30.
26. Iadecola C, Gorelick PB. Hypertension, angiotensin, and stroke: beyond blood pressure. Stroke. 2004;35(2):348-350.
27. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack [published corrections appear in Lancet. 2001;358(9292):1556 and 2002;359(9323):2120]. Lancet. 2001;358(9287):1033-1041.
28. Henyan NN, Riche DM, East HE, Gann PN. Impact of statins on risk of stroke: a meta-analysis. Ann Pharmacother. 2007 Dec;41(12):1937-1945. Epub 2007 Nov 6.
29. Amarenco P, Bogousslavsky J, Callahan A III, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-559.
30. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363(9411):757-767.
31. Crouse JR III, Byington RP, Furberg CD. HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data [published correction appears in Atherosclerosis. 1998;140(1):193-194]. Atherosclerosis. 1998;138(1):11-24.
32. Tsuchiya A, Nagotani S, Hayashi T, et al. Macrophage infiltration, lectin-like oxidized-LDL receptor-1, and monoctye chemoattractant protein-1 are reduced by chronic HMG-CoA reductase inhibition. Curr Neurovasc Res. 2007;4(4):268-273.
33. Corsini A, Pazzucconi F, Arnaboldi L, et al. Direct effects of statins on the vascular wall. J Cardiovasc Pharmacol. 1998;31(5):773-778.
34. Bang OY, Saver JL, Liebeskind DS, et al. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis [published correction appears in Neurology. 2007;68(18):1547]. Neurology. 2007 Mar;68(10):737-742. Epub 2006 Dec 20.
35. Goldstein LB. Low LDL cholesterol, statins, and brain hemorrhage: should we worry [editorial]? Neurology. 2007;68(10):719-720.
36. Bloomfield Rubins H, Davenport J, Babikian V, et al; VA-HIT Study Group. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation. 2001;103(23):2828-2833.
37. Gagné C, Bays HE, Weiss SR, et al; Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002;90(10):1084-1091.
38. Miller M. Niacin as a component of combination therapy for dyslipidemia. Mayo Clin Proc. 2003;78(6):735-742.
39. Hillen T, Coshall C, Tilling K, Rudd AG, McGovern R, Wolfe CD; South London Stroke Register. Cause of stroke recurrence is multifactorial: patterns, risk factors, and outcomes of stroke recurrence in the South London Stroke Register. Stroke. 2003 Jun;34(6):1457-1463. Epub 2003 May 15.
40. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology. 1998;50(1):208-216.
41. Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Horwitz RI. Insulin resistance and risk for stroke. Neurology. 2002;59(6):809-815.
42. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349-1357.
43. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329(5):304-309.
44. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005-2016.
45. Pyǒrälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) [published correction appears in Diabetes Care. 1997;20(6):1048]. Diabetes Care. 1997;20(4):614-620.
46. Curb JD, Pressel SL, Cutler JA, et al; Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension [published correction appears in JAMA. 1997;277(17):1356]. JAMA. 1996;276(23):1886-1892.
47. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383-393.
48. Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation and decreased risk of stroke in women. JAMA. 1993;269(2):232-236.
49. Wolf PA, D'Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor for stroke: the Framingham Study. JAMA. 1988;259(7):1025-1029.
50. You RX, Thrift AG, McNeil JJ, Davis SM, Donnan GA; Melbourne Stroke Risk Factor Study (MERFS) Group. Ischemic stroke risk and passive exposure to spouses' cigarette smoking. Am J Public Health. 1999;89(4):572-575.
51. Nides M, Leischow S, Sarna L, Evans SE. Maximizing smoking cessation in clinical practice: pharmacologic and behavioral interventions. Prev Cardiol. 2007;10(2)(suppl 1):23-30.
52. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
53. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345(17):1243-1249.
54. ESPRIT Study Group. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol. 2007;6(2):115-124.
55. Algra A, De Schryver EL, van Gijn J, Kappelle LJ, Koudstaal PJ. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischemic attack or minor stroke of presumed arterial origin. Stroke. 2003;34(1):234-235.
56. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352(13):1305-1316.
57. Mohr JP, Thompson JLP, Lazar RM, et al; Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345(20):1444-1451.
58. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86.
59. Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med. 1991;325(18):1261-1266.
60. SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet. 1991;338(8779):1345-1349.
61. Sze PC, Reitman D, Pincus MM, Sacks HS, Chalmers TC. Antiplatelet agents in the secondary prevention of stroke: meta-analysis of the randomized control trials. Stroke. 1988;19(4):436-442.
62. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143(1-2):1-13.
63. ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367(9523):1665-1673.
64. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989;1(8649):1215-1220.
65. Hass WK, Easton JD, Adams HP, et al; Ticlopidine Aspirin Stroke Study Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med. 1989;321(8):501-507.
66. Gorelick PB, Richardson D, Kelly M, et al; African American Antiplatelet Stroke Prevention Study (AAASPS) Investigators. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA. 2003;289(22):2947-2957.
67. Harker LA, Boissel J-P, Pilgrim AJ, Gent M; CAPRIE Steering Committee and Investigators. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. Drug Saf. 1999;21(4):325-335.
68. Zakarija A, Bandarenko N, Pandey DK, et al. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke. 2004 Feb;35(2):533-537. Epub 2004 Jan 5.
69. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329-1339.
70. Sacco RL, Diener HC, Yusuf S, et al; PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359(12):1238-1251. Epub 2008 Aug 27.
71. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction) [published correction appears in Circulation. 2008;117(9):e180]. Circulation. 2007 Aug 14;116(7):e148-e304. Epub 2007 Aug 6.
72. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, writing on behalf of the 2004 Writing Committee [published correction appears in Circulation. 2008;117(6):e162]. Circulation. 2008 Jan 15;117(2):296-329. Epub 2007 Dec 10.
73. Diener H-C, Bogousslavsky J, Brass LM, et al; MATCH Investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331-337.
74. Bhatt DL, Fox KA, Hacke W, et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006 Apr 20;354(16):1706-1717. Epub 2006 Mar 12.
75. Bhatt DL, Flather MD, Hacke W, et al; CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007 May 15; 49(19):1982-1988. Epub 2007 Apr 11.
76. Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation. 2005 May 3;111(17):2233-2240. Epub 2005 Apr 25.
77. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM; FASTER Investigators. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol. 2007 Nov;6(11):961-969. Epub 2007 Oct 10.
78. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325(7):445-453.
79. European Carotid Surgery Trialists' Collaborative Group. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet. 1998;351(9113):1379-1387.
80. EC/IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke: results of an international randomized trial. N Engl J Med. 1985;313(19):1191-1200.
81. Grubb RL Jr. Extracranial-intracranial arterial bypass for treatment of occlusion of the internal carotid artery. Curr Neurol Neurosci Rep. 2004;4(1):23-30.
82. SPACE Collaborative Group. 30 Day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial [published correction appears in Lancet. 2006;368(9543):1238]. Lancet. 2006;368(9543):1239-1247.
83. Mas J-L, Chatellier G, Beyssen B, et al; EVA-3S Investigators. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med. 2006;355(16):1660-1671.
84. Yadav JS, Wholey MH, Kuntz RE, et al; Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy Investigators. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med. 2004;351(15):1493-1501.
85. Chastain HD II, Campbell MS, Iyer S, et al. Extracranial vertebral artery stent placement: in-hospital and follow-up results. J Neurosurg. 1999;91(4):547-552.
86. de Rochemont Rdu M, Turowski B, Buchkremer M, Sitzer M, Zanella FE, Berkfeld J. Recurrent symptomatic high-grade intracranial stenoses: safety and efficacy of undersized stents-initial experience. Radiology. 2004;231(1):45-49.
87. Malek AM, Higashida RT, Phatouros CC, et al. Treatment of posterior circulation ischemia with extracranial percutaneous balloon angioplasty and stent placement. Stroke. 1999;30(10):2073-2085.
88. Mori T, Kazita K, Mori K. Cerebral angioplasty and stenting for intracranial vertebral atherosclerotic stenosis. AJNR Am J Neuroradiol. 1999;20(5):787-789.